Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849716 · ClinicalTrials.gov registry record
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)
A clinical trial of Dermatitis, Atopic, sponsored by Sanofi.
- Active
- Registry status
- 266
- Enrollment target
- 20
- Study locations
NCT03849716: Active study of Dermatitis, Atopic, sponsored by Sanofi.
NCT03849716 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 266 participants, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03849716, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- 266 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
Primary Outcome
Identification of biomarkers associated with demographic characteristics
Conditions Studied
Interventions
- OTHER Blood sample
- OTHER Cheek swab
Study Locations (20)
Florida
- Amedica Research Institute, Inc. Site Number : 8400067 - Hialeah
- Eastern Research, Inc. Site Number : 8400032 - Hialeah
- Vista Health Research, LLC Site Number : 8400034 - Miami
- Pediatric & Adult Research Center Site Number : 8400040 - Orlando
Alabama
- C Squared Research Center Site Number : 8400068 - Birmingham
- Cahaba Dermatology Site Number : 8400046 - Birmingham
- C2 Research Center, LLC Site Number : 8400071 - Montgomery
California
- Axis Clinical Trials Site Number : 8400025 - Los Angeles
- Madera Family Medical Group Site Number : 8400054 - Madera
- Fomat Medical Research, Inc. Site Number : 8400033 - Oxnard
Georgia
- Georgia Pollens Clinical Research Centers, Inc. Site Number : 8400057 - Albany
- IACT Health Site Number : 8400056 - Columbus
Illinois
- Northwestern University Feinberg School of Medicine Site Number : 8400001 - Chicago
- NorthShore University HealthSystem Site Number : 8400064 - Skokie
New York
- Philip Fried, M.D., PLLC Site Number : 8400029 - The Bronx
- Tiga Pediatrics, PC Site Number : 8400037 - The Bronx
Ohio
- Cincinnati Children's Hospital Medical Center Site Number : 8400017 - Cincinnati
- Dermatology Associates of Mid-Ohio Site Number : 8400052 - Marion
South Carolina
- MUSC Site Number : 8400013 - Charleston
- Allergic Disease and Asthma Research Center, PA Site Number : 8400048 - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 266 participants |
| Start Date | 2019-04-05 |
| Est. Completion | 2026-09-30 |
What the registry record for NCT03849716 still lists
NCT03849716 is an observational study that tracks outcomes without assigning an intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Blood sample is the first listed.
NCT03849716 names 20 study sites across 8 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03849716 about?
NCT03849716 is a clinical study titled "Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)". Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.
What is the current status of trial NCT03849716?
This trial is currently active not recruiting. The enrollment target is 266 participants. The study started on 2019-04-05. Estimated completion is 2026-09-30.
What conditions does trial NCT03849716 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03849716?
The interventions under investigation include: Blood sample (OTHER), Cheek swab (OTHER).
Who is sponsoring clinical trial NCT03849716?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849716 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03849716's enrollment target sits among peer trials
266 11th of 29 higher than 19 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05098652 · 266 participants · NA
Coaching Dementia Caregivers to Master Care-Resistant Behavior
- NCT06088277 · 266 participants · NA
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
- NCT06261814 · 266 participants · Phase 2
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors
- NCT06312124 · 266 participants · NA
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI